Phase 1-2 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer.
Phase of Trial: Phase I/II
Latest Information Update: 15 May 2017
At a glance
- Drugs Everolimus (Primary) ; Cyclophosphamide
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms Everolimus-LDcyclo
- 10 Jun 2017 Biomarkers information updated
- 09 May 2017 Status changed from recruiting to completed.
- 29 Apr 2016 Planned End Date changed from 1 Jan 2016 to 1 Jan 2017.